Chemokines are small secreted proteins that function in leukocyte trafficking, recruitment, and activation and have a role in many pathophysiological processes such as infectious and autoimmune diseases, inflammation, cancer, and vascular disease.
Naturally occurring modifications, such as N-terminal truncation, can affect the biological potency and the receptor specificity of chemokines.
R&D Systems is the only company that offers an extensive list of modified chemokines.
Browse our complete line of chemokine-related products
 View Larger Fig. 1 Recombinant Human CXCL1/GRO alpha chemoattracts BaF3 mouse pro B cells transfected with human CXCR2. The N-terminal truncated version (9196-GR) increases activity by 7-fold. |
 View Larger Fig. 2 Recombinant Human CXCL3/GRO gamma chemoattracts BaF3 mouse pro B cells transfected with human CXCR2. The N-terminal truncated version (8297-GG) increases activity by 7-fold. |
 View Larger Fig. 3 Recombinant Mouse LIX chemoattracts BaF3 mouse pro B cells transfected with human CXCR2. The N-terminal truncated form (9194-MC) increases activity by 10-fold. |
Available Chemokines and the Effect of Modification
| Recombinant Chemokines (amino acids) | Species | Catalog Number | Effect of modification ED50/Specificity |
| CCL14a/HCC-1 (aa 20-93) | Human | 324-HC | 200-800 ng/ml |
| CCL14a/HCC-1 (aa 28-93) | Human | 1578-HC | 0.15-0.75 ng/ml |
| CCL15/MIP-1 delta (aa 22-113) | Human | 363-MG | 2-8 ng/ml |
| CCL15/MIP-1 delta (aa 46-113) | Human | 628-LK | 0.6-3 ng/ml |
| CCL24/MPIF-2 (aa 24-119) | Mouse | 528-MP | 150-600 ng/ml |
| CCL24/MPIF-2 (aa 27-119) | Mouse | 1017-MP | 1-5 ng/ml |
| CCL4/MIP-1 beta (aa 24-92) | Human | 271-BME | Ligand for CCR5 |
| CCL4/MIP-1 beta (aa 26-92) | Human | 8228-MB | Ligand for CCR1 and CCR5 |
| CCL6/C10 (aa 22-116) | Mouse | 487-C | 50-250 ng/ml |
| CCL6/C10 (aa 42-116) | Mouse | 3210-c | 0.5-2 ng/ml |
| CCL9/MIP-1 gamma (aa 22-122) | Mouse | 463-MG | 2-10 ng/ml |
| CCL9/MIP-1 gamma (aa 50-122) | Mouse | 3217-MG | 0.2-1 ng/mL |
| CX3CL1/Fractalkine (aa 22-102) | Mouse | 458-MF | 10-50 ng/ml |
| CX3CL1/Fractalkine (aa 25-102) | Mouse | 571-MF | 4-20 ng/ml |
| CX3CL1/Fractalkine (aa 29-102) | Mouse | 3215-MF | CX3CR1 antagonist |
| CX3CL1/Fractalkine (aa 22-100) | Rat | 568-FR | 15-75 ng/ml |
| CX3CL1/Fractalkine (aa 25-100) | Rat | 537-FT | 3-18 ng/ml |
| CXCL1/GRO alpha (aa 35-107) | Human | 275-GR | 1-4 ng/mL |
| CXCL1/GRO alpha (aa 39-107) | Human | 9196-GR | 0.15-0.9 ng/mL |
| CXCL1/KC (aa 20-96) | Mouse | 453-KC | 3-15 ng/ml |
| CXCL1/KC (aa 29-96) | Mouse | 1395-KC | 0.8-4 ng/ml |
| CXCL12/SDF1 beta (aa 19-93) | Human/Feline | 2716-SD | 150-600 ng/ml |
| CXCL12/SDF1 beta (aa 22-93) | Human/Feline | 351-FS | 1-5 ng/ml |
| CXCL2/GRO beta (aa 35-107) | Human | 276-GB | 3-15 ng/ml |
| CXCL2/GRO beta (aa 39-107) | Human | 176-GB | 1-5 ng/ml |
| CXCL3/GRO gamma (aa 35-107) | Human | 277-GG | 2-10 ng/ml |
| CXCL3/GRO gamma (aa 39-107) | Human | 8297-GG | 0.4-2.4 ng/ml |
| CXCL5/ENA-70 (aa 45-114) | Human | 649-EN | 0.15-0.75 ng/ml |
| CXCL5/ENA-74 (aa 41-114) | Human | 651-NA | 0.3-1.5 ng/ml |
| CXCL5/ENA-78 (aa 37-114) | Human | 254-XB | 3-15 ng/ml |
| CXCL7/Thymus Chemokine-1 (aa 40-113) | Mouse | 793-CK | 200-1000 ng/ml |
| CXCL7/Thymus Chemokine-1 (aa 48-109) | Mouse | 1091-CK | 1-5 ng/ml |
| CXCL8/IL-8 (aa 23-99) | Human | 618-IL | 1-5 ng/ml |
| CXCL8/IL-8 (aa 28-99) | Human | 208-IL | 0.5-2.5 ng/ml |
| LIX (aa 45-118) | Mouse | 433-MC | 30-100 ng/mL |
| LIX (aa 49-118) | Mouse | 9194-MC | 1.5-9 ng/mL |
New Chemokines Expressed in Mammalian Cell Lines
| Recombinant Protein | Species | Source | Catalog Number |
| CXCL4 /PF4 (aa 32-101) | Human | HEK293 | 7989-P4 |
| XCL2 /SCM-1 beta (aa 22-114) | Human | HEK293 | 8418-X2 |